Long-term outcomes of alemtuzumab in relapsing-remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab.
Gaggiola M, Mauceri V A, Zanotelli G, Zoccarato M, Gallo P, Rinaldi F, Perini P, Puthenparampil M
J Neurol Sci. 2026 Oct 08; 491:126210. PMID: 42868842.Abstract
